Glucose Lowering, Hypoglycemia, and Cardiovascular Disease Risk

Current Cardiovascular Risk Reports

Volumn 4, Issue 2, 2010, Pages 159-164

  Reboldi, Gianpaolo ^a   Gentile, Giorgio ^a   Angeli, Fabio ^b   Mazzotta, Giovanni ^b   Martire, Paola ^b   Garofoli, Marta ^b   Verdecchia, Paolo ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Glycosylated hemoglobin; Hypoglycemia

Indexed keywords

EID: 84873526452     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-010-0077-9     Document Type: Review

References (39)

1. Steinbrook R: Facing the diabetes epidemic-mandatory reporting of glycosylated hemoglobin values in New York City. N Engl J Med 2006, 354: 545-548.
2. Gan D: Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2003.
3. •• Buse JB, Ginsberg HN, Bakris GL, et al.: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115: 114-126. In this article, the ADA and American Heart Association attempt to harmonize the recommendations for CVD prevention in people with diabetes.
4. American Diabetes Association: Economic costs of diabetes in the U. S. in 2007. Diabetes Care 2008, 31: 596-615. (Published erratum appears in Diabetes Care 2008, 31: 1271.).
5. Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27: 1047-1053.
6. Bunce C, Wormald R: Causes of blind certifications in England and Wales: April 1999-March 2000. Eye (Lond) 2008, 22: 905-911.
7. Tomson C, Ford D, Ansell D: The UK Renal Registry: an overview. Br J Hosp Med (Lond) 2008, 69: 548-549.
8. Centers for Disease Control and Prevention (CDC): Racial differences in trends of end-stage renal disease, by primary diagnosis-United States, 1994-2004. MMWR Morb Mortal Wkly Rep 2007, 56: 253-256.
9. Williamson DF, Vinicor F, Bowman BA; Centers for Disease Control and Prevention Primary Prevention Working Group: Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implications for health policy. Ann Intern Med 2004, 140: 951-957.
10. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37: 1053-1059. (Published erratum appears in Hypertension 2001, 37: 1350.).
11. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287: 2570-2581.
12. Rosamond W, Flegal K, Friday G, et al.: Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115: e69-e171.
13. Movahed MR, Hashemzadeh M, Jamal MM: Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005, 105: 315-318.
14. Roglic G, Unwin N, Bennett PH, et al.: The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005, 28: 2130-2135.
15. Sowers JR: Treatment of hypertension in patients with diabetes. Arch Intern Med 2004, 164: 1850-1857.
16. Yusuf S, Hawken S, Ounpuu S, et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364: 937-952.
17. DCCT SG. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329: 977-986.
18. Edic SG. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000, 342: 381-389. (Published erratum appears in N Engl J Med 2000, 342: 1376.).
19. UKPDS SG. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352: 837-853. (Published erratum appears in Lancet 1999, 354: 602.).
20. UKPDS SG. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352: 854-865. (Published erratum appears in Lancet 1998, 352: 1558.).
21. Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28: 103-117.
22. •• Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358: 2545-2559. In the ACCORD trial, the use of intensive therapy to target normal glycated hemoglobin levels increased mortality and did not significantly reduce major cardiovascular events.
23. •• Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358: 2560-2572. In the ADVANCE trial, intensive glucose control yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy.
24. Meinert CL, Knatterud GL, Prout TE, Klimt CR: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970, 19(Suppl): 789-830.
25. Leibel B: An analysis of the University Group Diabetes Study Program: data results and conclusions. Can Med Assoc J 1971, 105: 292-294.
26. Karam JH, Matin SB, Forsham PH: Antidiabetic drugs after the University Group Diabetes Program (UGDP). Ann Rev Pharmacol 1975, 15: 351-366.
27. Prout TE, Knatterud GL, Meinert CG: Diabetes drugs: clinical trial. Science 1979, 204: 362-363.
28. •• Holman RR, Paul SK, Bethel MA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359: 1577-1589. This article reports results of the extension phase of the UKPDS study: the legacy effect.
29. •• Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360: 129-139. (Published erratum appears in N Engl J Med 2009, 361: 1028 and N Engl J Med 2009, 361: 1024-1025.) In the VADT trial, intensive glucose control in patients with poorly controlled type 2 diabetes had no significant effect on fatal and nonfatal cardiovascular events.
30. Bloomgarden ZT: Glycemic control in diabetes: a tale of three studies. Diabetes Care 2008, 31: 1913-1919.
31. Patel A, MacMahon S, Chalmers J, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370: 829-840.
32. • Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358: 580-591. These are the results of the long-term follow-up of the Steno-2 study.
33. •• Nathan DM, Zinman B, Cleary PA, et al.: Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience (1983-2005). Arch Intern Med 2009, 169: 1307-1316. This article provides the results of the DCCT 30-year follow-up. The frequencies of serious complications in patients with type 1 diabetes mellitus, especially when treated intensively, are lower than reported historically.
34. •• Kelly TN, Bazzano LA, Fonseca VA, et al.: Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151: 394-403. In this systematic review and meta-analysis of major intervention studies, intensive glucose control does not reduce the risk for cardiovascular death or mortality, and increases the risk for severe hypoglycemia.
35. • Ray KK, Seshasai SR, Wijesuriya S, et al.: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373: 1765-1772. In this meta-analysis of five intervention studies, intensive glycemic control does not increase mortality risk.
36. American Diabetes Association: Standards of medical care in diabetes-2009. Diabetes Care 2009, 32(Suppl 1): S13-S61.
37. Adler GK, Bonyhay I, Failing H, et al.: Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 2009, 58: 360-366.
38. Montori VM, Fernandez-Balsells M: Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med 2009, 150: 803-808. (Published erratum appears in Ann Intern Med 2009, 151: 144.).
39. •• Skyler JS, Bergenstal R, Bonow RO, et al.: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009, 119: 351-357. (Published erratum appears in Circulation 2009, 119: e605.) This is the ADA, American College of Cardiology, and American Heart Association joint statement following the publication of ACCORD, ADVANCE, and VADT, recommending less aggressive glycemic targets.